Skip to main
RNAC

RNAC Stock Forecast & Price Target

RNAC Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cartesian Therapeutics, Inc. is showing substantial promise due to positive Phase 2b data indicating sustained clinically meaningful improvements, with a notable average reduction of 4.8 in MG-ADL scores at 12-month dosing intervals. Furthermore, the differentiated profile of Descartes-08 supports its potential for broader patient uptake, particularly in biologic-naive patients, while maintaining a clean safety profile over time with no significant adverse events reported. The firm's proprietary ImmTOR immune tolerance platform, combined with strong biomarker data demonstrating effective immune modulation, underscores a solid foundation for future growth and market penetration within the biopharmaceutical sector.

Bears say

Cartesian Therapeutics Inc. experienced a decline in cash, cash equivalents, and restricted cash from $162.1 million in the second quarter of 2025 to $145.1 million in the third quarter of 2025, indicating significant operational spending as the Phase 3 program for myasthenia gravis ramps up. The company’s market capitalization is under $200 million, leading to a notably low enterprise value of approximately $50 million, which reflects investors' skepticism regarding the value of its lead asset, Descartes-08, in myasthenia gravis despite its regulatory designations. Furthermore, with a revised terminal growth rate expectation cut from 3% to 1%, Cartesian Therapeutics faces challenges in capturing market interest amid unfavorable perceptions of current treatment options and patient burden.

RNAC has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cartesian Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cartesian Therapeutics Inc (RNAC) Forecast

Analysts have given RNAC a Strong Buy based on their latest research and market trends.

According to 4 analysts, RNAC has a Strong Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cartesian Therapeutics Inc (RNAC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.